scholarly journals Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up

2021 ◽  
Author(s):  
Dominik A. Barth ◽  
Nazanin Sareban ◽  
Andrea K. Lindner ◽  
Louisa A.J. Daller ◽  
Eva Maria Matzhold ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Blood Group ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Abo Blood Group ◽  
Blood Group System ◽  
Long Term Follow Up

Long term follow up of 50 patients with metastatic renal cell carcinoma treated with high dose i.v. interleukin. 2

1999 ◽  
Vol 35 ◽  
pp. S358
Author(s):  
M. Libra ◽  
A. Buonadonna ◽  
A. Freschi ◽  
A. Bearz ◽  
M. Berretta ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
High Dose ◽  
Long Term Follow Up

scholarly journals Succinate Dehydrogenase–Deficient Renal Cell Carcinoma

2018 ◽  
Vol 143 (5) ◽  
pp. 643-647 ◽  
Author(s):  
Tsung-Heng Tsai ◽  
Wen-Ying Lee
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Succinate Dehydrogenase ◽  
Renal Cell ◽  
World Health ◽  
Low Grade ◽  
Long Term Follow Up ◽  
Health Organization

Succinate dehydrogenase (SDH)–deficient renal cell carcinoma is a recently recognized distinct subtype of renal cell carcinoma in the 2016 World Health Organization classification. It is associated with SDH gene germline mutations, which also cause paraganglioma/pheochromocytoma, gastrointestinal stromal tumor, and pituitary adenoma. The tumor most commonly presents in young adulthood. The tumors are arranged in solid nests or in tubules and frequently show cystic change. The tumors are composed of cuboidal to oval cells with round nuclei, dispersed chromatin, and inconspicuous nucleoli. The cytoplasm is eosinophilic or flocculent but not truly oncocytic. The most distinctive histologic feature is the presence of cytoplasmic vacuoles or inclusions. Loss of SDH subunit B immunostaining is needed for a definite diagnosis. The prognosis is good for low-grade tumors but worse for tumors with high-grade nuclei, sarcomatoid change, or coagulative necrosis. Long-term follow-up is indicated.

scholarly journals Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer ◽  
2020 ◽  
Vol 126 (18) ◽  
pp. 4156-4167 ◽  
Author(s):  
Robert J. Motzer ◽  
Bernard Escudier ◽  
Saby George ◽  
Hans J. Hammers ◽  
Sandhya Srinivas ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Long Term Follow Up

Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up

2012 ◽  
Vol 11 (3) ◽  
pp. 387-394 ◽  
Author(s):  
C. A. Jilg ◽  
Hartmut P. H. Neumann ◽  
S. Gläsker ◽  
O. Schäfer ◽  
C. Leiber ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Nephron Sparing Surgery ◽  
Von Hippel Lindau ◽  
Nephron Sparing ◽  
Long Term Follow Up

UP-01.160 Long-Term Follow-Up Is Necessary for Patients Presenting With pT1 and pT2 Renal Cell Carcinoma

Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S239-S240
Author(s):  
S. Nestler ◽  
C. Thomas ◽  
W. Jäger ◽  
W. Brenner ◽  
C. Hampel ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document